Clinical Trial Update: ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A completed Phase II trial comparing weekly versus every-three-week docetaxel and cisplatin, followed by gemcitabine, in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sanofi | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED